MedTrace Logo

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2026-04-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Conditions

  • Focal Epilepsy

Interventions

DRUG

BHV-7000

BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily

DRUG

BHV-7000

BHV-7000 75 mg. Participants will take blinded investigational product (IP) once daily

DRUG

Placebo

Matching placebo taken once daily

Sponsors & Collaborators

  • Biohaven Therapeutics Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-13
Primary Completion
2026-05-31
Completion
2026-05-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Denmark
  • Finland
  • Germany
  • Greece
  • Hungary
  • India
  • Italy
  • Mexico
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06309966 on ClinicalTrials.gov